-
公开(公告)号：US20110098289A1
公开(公告)日：2011-04-28
申请号：US12986043
申请日：2011-01-06
IPC分类号： A61K31/5375 , A61P3/04 , A61P9/12 , A61K31/423
CPC分类号： A61K31/423 , A61K31/12 , A61K31/135 , A61K31/255 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/5375 , A61K31/7024 , A61K45/06 , A61K2300/00
摘要： The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
摘要翻译： 本发明一般涉及使用例如单独使用唑尼沙胺或其他减肥促进性抗惊厥药来治疗肥胖并最小化代谢危险因素的方法，或与安非他酮或其代谢物或其它增强活性的化合物 去甲肾上腺素和/或多巴胺通过吸收抑制或其他机制。
-
2.发明申请COMPOSITIONS OF AN ANTICONVULSANT AND MIRTAZAPINE TO PREVENT WEIGHT GAIN 审中-公开安非他明和咪唑他宁的组合物，以防止体重增加公开(公告)号：US20100179129A1
公开(公告)日：2010-07-15
申请号：US12732901
申请日：2010-03-26
CPC分类号： A61K31/19 , A61K31/137 , A61K31/155 , A61K31/352 , A61K31/42 , A61K31/423 , A61K31/425 , A61K31/435 , A61K31/55 , A61K31/551 , A61K31/7008 , A61K33/00 , A61K45/06 , A61K2300/00
摘要： Disclosed are pharmaceutical compositions comprising mirtazapine and an anticonvulsant drug. Also disclosed are methods of preventing weight gain associated with the administration of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug. Further disclosed are methods of increasing the efficacy of mirtazapine comprising identifying a patient to whom mirtazapine is to be administered and administering to said patient a pharmaceutical composition comprising mirtazapine and an anticonvulsant drug.
摘要翻译： 公开了包含米氮平和抗惊厥药物的药物组合物。 还公开了防止与米氮平给药相关的体重增加的方法，包括鉴定要给予米氮平的患者，并向所述患者施用包含米氮平和抗惊厥药物的药物组合物。 进一步公开的是增加米氮平的功效的方法，其包括鉴定要给予米氮平的患者和向所述患者施用包含米氮平和抗惊厥药物的药物组合物。
-
公开(公告)号：US20090076108A1
公开(公告)日：2009-03-19
申请号：US12265626
申请日：2008-11-05
IPC分类号： A61K31/42 , A61K31/137
CPC分类号： A61K31/423 , A61K31/12 , A61K31/135 , A61K31/255 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/5375 , A61K31/7024 , A61K45/06 , A61K2300/00
摘要： The present invention relates generally to methods of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight loss-promoting anti-convulsant either alone or in combination with bupropion or metabolites thereof or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
摘要翻译： 本发明一般涉及使用例如单独使用唑尼沙胺或其他减肥促进性抗惊厥药来治疗肥胖并最小化代谢危险因素的方法，或与安非他酮或其代谢物或其它增强活性的化合物 去甲肾上腺素和/或多巴胺通过吸收抑制或其他机制。
-
公开(公告)号：US07109198B2
公开(公告)日：2006-09-19
申请号：US10440404
申请日：2003-05-19
IPC分类号： A61K31/535 , A61K31/42 , A61K31/135
CPC分类号： A61K45/06 , A61K31/137 , A61K31/255 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/423 , A61K31/7024 , A61K2300/00
摘要： The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
-
公开(公告)号：US20080319036A1
公开(公告)日：2008-12-25
申请号：US12205769
申请日：2008-09-05
IPC分类号： A61K31/423 , A61P31/04
CPC分类号： A61K45/06 , A61K31/137 , A61K31/255 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/423 , A61K31/7024 , A61K2300/00
摘要： The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
-
公开(公告)号：US07425571B2
公开(公告)日：2008-09-16
申请号：US10830071
申请日：2004-04-23
IPC分类号： A61K31/42
CPC分类号： A61K45/06 , A61K31/137 , A61K31/255 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/423 , A61K31/7024 , A61K2300/00
摘要： The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
摘要翻译： 本发明一般涉及肥胖症，特别涉及一种治疗肥胖症的方法，并且使用例如单独使用唑尼沙胺或其他减肥促进抗惊厥药与安非他酮或安非他酮组合使用的与之相关的代谢危险因素最小化 通过吸收抑制或其他机制增强去甲肾上腺素和/或多巴胺活性的其他化合物。
-
公开(公告)号：US20080188476A1
公开(公告)日：2008-08-07
申请号：US11381990
申请日：2006-05-05
IPC分类号： A61K31/5375 , A61K31/42 , A61P3/04
CPC分类号： A61K45/06 , A61K31/137 , A61K31/255 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/423 , A61K31/7024 , A61K2300/00
摘要： The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
摘要翻译： 本发明一般涉及肥胖症，特别涉及一种治疗肥胖症的方法，并且使用例如单独使用唑尼沙胺或其他减肥促进抗惊厥药与安非他酮或安非他酮组合使用的与之相关的代谢危险因素最小化 通过吸收抑制或其他机制增强去甲肾上腺素和/或多巴胺活性的其他化合物。
-
公开(公告)号：US08394354B2
公开(公告)日：2013-03-12
申请号：US12300000
申请日：2007-05-08
申请人： Lisa A. Paige , Matthew W. Mitchell , Anne Evans , Don Harvan , David Carl Steffens , K. Ranga R. Krishnan , Rima Kaddurah-Daouk
发明人： Lisa A. Paige , Matthew W. Mitchell , Anne Evans , Don Harvan , David Carl Steffens , K. Ranga R. Krishnan , Rima Kaddurah-Daouk
CPC分类号： G01N33/6893 , G01N2500/10 , G01N2800/304 , G01N2800/50 , G01N2800/52 , G01N2800/56
摘要： The present invention provides various biomarkers of depression. The present invention also provides various methods of using the biomarkers, including methods for diagnosis of depression, methods of determining predisposition to depression, methods of monitoring progression/regression of depression, methods of assessing efficacy of compositions for treating depression, methods of screening compositions for activity in modulating biomarkers of depression, methods of treating depression, as well as other methods based on biomarkers of depression.
摘要翻译： 本发明提供了各种抑郁症生物标志物。 本发明还提供使用生物标志物的各种方法，包括用于诊断抑郁症的方法，确定抑郁倾向的方法，监测抑郁进展/消退的方法，评价组合物治疗抑郁症的功效的方法，筛选组合物的方法 调节抑郁生物标志物的活性，抑郁症的治疗方法以及基于抑郁症生物标志物的其他方法。
-
9.发明授权Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss 失效抗惊厥药和抗精神病药物的组合物及其用于影响体重减轻的方法公开(公告)号：US07429580B2
公开(公告)日：2008-09-30
申请号：US11034316
申请日：2005-01-11
IPC分类号： A61K31/553 , A61K31/55 , A61K31/497 , A61K31/42 , A01N43/00 , A01N43/62 , A01N43/80
CPC分类号： A61K45/06 , A61K31/137 , A61K31/155 , A61K31/19 , A61K31/352 , A61K31/42 , A61K31/423 , A61K31/425 , A61K31/435 , A61K31/55 , A61K31/551 , A61K31/7008 , A61K33/00 , A61K2300/00
摘要： Disclosed are compositions for affecting weight loss comprising a first compound and a second compound, where the first compound is a psychotherapeutic agent and the second compound is a anticonvulsant. Also disclosed are methods of affecting weight loss, increasing energy expenditure, increasing satiety in an individual, or suppressing the appetite of an individual, comprising identifying an individual in need thereof and treating that individual with a psychotherapeutic agent and an anticonvulsant.
摘要翻译： 公开了用于影响体重减轻的组合物，其包含第一化合物和第二化合物，其中第一化合物是精神治疗药物，第二化合物是抗惊厥药。 还公开了影响体重减轻，增加能量消耗，增加个体饱腹感或抑制个体食欲的方法，其包括鉴定有需要的个体并用精神治疗剂和抗惊厥剂治疗该个体。
-
公开(公告)号：US07754748B2
公开(公告)日：2010-07-13
申请号：US12205769
申请日：2008-09-05
IPC分类号： A61K31/42
CPC分类号： A61K45/06 , A61K31/137 , A61K31/255 , A61K31/35 , A61K31/357 , A61K31/42 , A61K31/423 , A61K31/7024 , A61K2300/00
摘要： The present invention relates, in general, to obesity, and, in particular, to a method of treating obesity and minimizing metabolic risk factors associated therewith using, for example, zonisamide or other weight-loss promoting anticonvulsant either alone or in combination with bupropion or other compound that enhances the activity of norepinephrine and/or dopamine via uptake inhibition or other mechanism.
摘要翻译： 本发明一般涉及肥胖症，特别涉及一种治疗肥胖症的方法，并且使用例如单独使用唑尼沙胺或其他减肥促进抗惊厥药与安非他酮或安非他酮组合使用的与之相关的代谢危险因素最小化 通过吸收抑制或其他机制增强去甲肾上腺素和/或多巴胺活性的其他化合物。
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.016 秒)